Skip Navigation
Department of Health and Human Services
Slide Tray
0 slides

Return to Slide Library


Add Presentation to Slide Tray Presentation:

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

Slide: 6 of 46

Treatment of JIA (2 of 2)

Anti-inflammatory drugs alone are often inadequate to relieve symptoms and limit progression of disease.

DMARDs are now in common use for JIA, and several have been approved by the U.S. Food and Drug Administration for this indication. DMARDs inhibit the immune cells and mechanisms underlying the symptoms of rheumatic disease. There are two classes of DMARDs: biologic and non-biologic.